Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen

Wang, Ange; Letourneau, Joseph M.; Juarez‐Hernandez, Flor; Abel, Mary Kathryn; Mok-Lin, Evelyn; Rosen, Mitchell P.

doi:10.1007/s10815-022-02626-6

Cited by 3 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 In contrast, some more recent randomised controlled studies have shown no effect on controlled ovarian stimulation with the addition of tamoxifen. 22,23 Given that all ER positive patients in our study were placed on tamoxifen while undergoing fertility preservation, it is unknown if the addition of this medication had contributed to the difference in ovarian stimulation outcomes.…”

Section: Discussionmentioning

confidence: 99%

Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference?

Sii

Polyakov

Rozen

et al. 2023

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

BackgroundThe presence of different breast cancer receptor status may impact ovarian stimulation outcomes.AimTo study the association between oestrogen receptor (ER) status in breast cancer patients and fertility preservation outcomes in a major tertiary referral centre.Materials and MethodsWomen who underwent fertility preservation following the diagnosis of breast cancer from 2008 to 2018 were included in the study. Patient age, ovarian stimulation parameters and laboratory outcomes were recorded and compared between the ER positive and negative groups. The primary outcome was total number of oocytes frozen. Secondary outcomes included total number of oocytes collected, mature oocytes, and embryos frozen.ResultsThe women included in the study (n = 214) were analysed in the following groups based on their fertility preservation method: oocyte freezing (n = 131), embryo freezing (n = 70), and both embryo and oocyte freezing (n = 13). There was an increase in the mean (but not mature) number of oocytes frozen (12.4 and 9.2, P‐value = 0.03) favouring the ER positive group, even though the women in this group were older (35.0 and 33.4, P‐value of 0.03). There is no difference in the starting follicle‐stimulating hormone dose, duration of stimulation, mature oocytes collected, and embryos frozen in both groups.ConclusionPatients with ER positive breast cancer may have more positive ovarian stimulation outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference?

Sii

Polyakov

Rozen

et al. 2023

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…Its most common application is as an adjunct treatment for breast cancer patients undergoing oocyte cryopreservation cycles. In this setting, letrozole is used to suppress plasma estrogen levels during controlled ovarian stimulation, which is an essential component of fertility preservation in breast cancer patients [ 11 , 12 ]. However, letrozole has also demonstrated efficacy in stimulating multifollicular growth through a variety of mechanisms.…”

Section: Introductionmentioning

confidence: 99%

“…One of the key mechanisms by which it achieves this effect is by competitively binding to the aromatase enzyme, thereby inhibiting the conversion of androstenedione and testosterone to estrone and estradiol. This results in increased intrafollicular concentrations of androgens, which can stimulate the proliferation of granulosa and theca cells, promote the growth of small follicles, and upregulate the expressions of FSH, IGF-I, and IGF-I receptors [ 11 , 12 , 13 , 14 , 15 ]. Moreover, letrozole has been shown to increase the central release of FSH by reducing the negative feedback effect of estradiol production by the ovary.…”

Section: Introductionmentioning

confidence: 99%

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

D’Amato¹,

Caringella²,

Stanziano³

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Background: In recent times, different novel GnRH-antagonist protocols with various combinations of gonadotropins and other molecules (e.g., aromatase inhibitors, selective estrogen receptor modulators) have been proposed for expected normal ovarian responders undergoing assisted reproductive treatments. The purpose of this study was to evaluate the effectiveness of a novel ovarian stimulation protocol based on the combination of corifollitropin-alfa plus five days of letrozole in E-NOR women undergoing IVF as compared with a daily recombinant-FSH regimen. Methods: We conducted a retrospective-controlled study on 182 couples undergoing their first IVF attempt. In Group A (experimental), letrozole (2.5 mg daily) was administered from day 2 (up to day 6 of the cycle), followed by corifollitropin-alfa on day 3 and daily recombinant FSH from day 10. In Group B, recombinant FSH from day 2 were administered (150 IU-225 IU daily). Statistical analysis was completed using SPSS Statistics. The primary outcome was the total number of MII oocytes retrieved. Results: Group A showed similar results compared to Group B in terms of MII oocytes, live birth, implantation, and clinical pregnancy rates (p = ns). Nevertheless, the experimental group was associated with a trend towards a higher number of developing follicles, total oocytes, and embryos (p < 0.05) with lower estradiol and progesterone values at ovulation induction compared to Group B, resulting in an increased chance of performing a fresh embryo transfer (p < 0.05). Conclusions: The combination of CFα plus five days of letrozole was associated with a trend towards a higher number of developing follicles, total oocytes, and obtained embryos. Moreover, the experimental protocol resulted in lower estradiol and progesterone values at ovulation induction compared to daily rFSH, with an increased chance of performing a fresh embryo transfer (with no OHSS occurrence). Given the observational design of our study, further well-conducted RCTs are needed.

show abstract

Research progress on fertility protection in patients with gynecological malignancies

WAN,

HUANG,

YANG

et al. 2023

Sci. Sin.-Vitae

View full text Add to dashboard Cite

Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen

Cited by 3 publications

References 39 publications

Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference?

Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference?

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

Research progress on fertility protection in patients with gynecological malignancies

Contact Info

Product

Resources

About